Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

Provided herein are topical formulations containing copper ions and methods of treating inflammatory, microbial, and arthritic conditions in various areas of the body using such formulations. Methods of treating osteoarthritis using topical copper ion treatments are provided. Methods of treating and preventing microbial infections using copper ion treatments are further provided, including methods of preventing biofilm. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension is combined with various carriers to form the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

This invention relates to cocrystals of naloxone and of naltrexone and their use as opioid antagonists. The cocrystals of the invention include naloxone isonicotinamide cocrystal, naloxone hydrochloride piperazine cocrystal, naltrexone menthol cocrystal, naltrexone thymine cocrystal, naltrexone 2,5-dihydroxybenzoic acid cocrystal, naltrexone salicylic acid cocrystal, naltrexone hydrochloride piperazine cocrystal and naltrexone hydrochloride sulfathiazole cocrystal. A drug-in¬ adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a cocrystal of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof. Also disclosed is an improved transdermal patch for administering fentanyl or an analog thereof, or for administering a mu opioid agonist, the improvement wherein the transdermal patch contains a cocrystal of the invention in an abuse limiting amount. The improved transdermal patch may be a drug-in-adhesive transdermal patch or a reservoir transdermal patch.

A bandage for delivering an anesthetic through a patient's skin at the site of a hypodermic injection prior to the administration of the hypodermic injection to alleviate pain due to the injection. The bandage has a first layer having a perimeter area adhesive, an anesthetic delivery layer disposed on the first layer inside the perimeter area and containing an anesthetic for delivery into the patient's skin, a first peel-off layer covering the anesthetic delivery layer for keeping the anesthetic delivery layer sterile until the peel-off layer is removed, the first layer being placed on the skin of the patient at the future site of the injection with the anesthetic delivery layer and adhesive being in contact with the skin of the patient thereby to adhere the bandage to the site and allow the anesthetic delivery layer to deliver the anesthetic into the skin, wherein the anesthetic delivery layer comprises a material for accelerating the delivery of the anesthetic into the patient's skin, the anesthetic delivery layer adapted to receive the injection therethrough after the skin has undergone numbing by the anesthetic.

The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.

The present invention relates to a transdermal therapeutic system for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; B) a rivastigmine-containing layer comprising at least one acrylic polymer; and C) a skin contact layer comprising at least one styrene-isoprene-styrene block copolymer and at least one tackifier.

The disclosure provides new medical device and manufacturing methods as well as chemicals that enhance delivery of pharmaceuticals from a transdermal patch, where the patch may include a film, adhesive, emulsifier, tackifier, or hydrogel.

An absorbent article comprising at least a topsheet layer and a backsheet layer, each layer having a first and a second surface, at least one of the layers has a composition comprising a skin beneficial agent printed on the first surface and an ink composition printed on the second surface, wherein the compositions on the first and the second surfaces respectively may be interchanged.

A method of selecting a surfactant system suitable for infants and young children is disclosed.